HF Advisory Group LLC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

HF Advisory Group LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,176 shares of the biopharmaceutical company’s stock after selling 1,737 shares during the quarter. HF Advisory Group LLC’s holdings in Gilead Sciences were worth $1,494,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of GILD. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth $25,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the 4th quarter worth $29,000. Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $33,000. Finally, Friedenthal Financial acquired a new position in shares of Gilead Sciences in the third quarter valued at about $50,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ GILD opened at $91.84 on Friday. The stock has a market cap of $114.46 billion, a PE ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a 50-day moving average of $91.75 and a 200 day moving average of $83.97.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.29 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.35%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Wells Fargo & Company upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Finally, Oppenheimer upped their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.